Clinical trial · Observational
The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19
The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19, a Prospective Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) emerged at December 2019 in Wuhan, China, and soon caused a large global outbreak. The delayed treatment for many chronic diseases, due to the concern of SARS-CoV-2 infection, is an increasing serious problem. Here the investigators investigate the safety of chemotherapy for patients with gynecological malignancy in Wuhan, the center of high-risk regions of COVID-19.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gynecological Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy | Drug | Chemotherapy | ALIAS |
Design
Arms and outcomes
Arms (2)
- label
- Chemotherapy group
- description
- Routine chemotherapy every 3 weeks for 2 cycles, and follow up for 2 weeks after discharge from hospital. Total observation duration is 6 weeks.
- interventionNames
- Drug: Chemotherapy
- label
- Control group
- description
- No treatment, based on patient's choice. Total observation duration is 6 weeks.
Primary outcomes (1)
- measure
- SARS-CoV-2 infection
- timeFrame
- through study completion, an average of 3 months.
- description
- Incidence rate of SARS-CoV-2 infection within the whole period of the study.
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patient is 18 to 80 years old female. * Patient must have histologically confirmed either type of gynecological malignancies. * Chemotherapy must be essential for the patient. Exclusion Criteria: * Diagnosed or suspected patients with covid-19 pneumonia, according to the symptom, nucleic acid tests, antibody tests for SARS-CoV-2, or CT scan of the lungs. * Patient has a prior SARS-CoV-2 infection without clinical cure for 28 days. * Patient has close contact with diagnosed or suspected SARS-CoV-2 infected person within 14 days. * Patient has inadequate general condition, severe complication or organ dysfunction not fit for chemotherapy (based on the judgment of researchers). * Patient or the family refuses to sign the informed consent. * Patient does not cooperate in following up.
References
Publications (0)
Data not yet available